Home » Stocks & Shares » Philips share price falls on disappointing Q1 results

Philips share price falls on disappointing Q1 results

**Weaker-than-expected top-line growth**

Philips reported Q1 organic sales growth of 0.2%. While management had warned for a slow start to the year, this was clearly below both our expectation (2.4%) and consensus (3.4%). Both healthcare at -2.1% (KECH and consensus 0.5%) and lighting at 0.4% (KECH 3.0%, consensus 4.3%) attributed to the weaker-than-expected top-line.
**Significant EBITA miss**

Adjusted EBITA amounted to EUR368m, 8% below our forecast of EUR402m and 12% below consensus of EUR420m. The miss was largely due to weaker-than-expected margins in healthcare (lower volumes, currency headwinds, production suspension) and to a lesser extent in lighting. Group adjusted EBITA margin dropped by 70bps to 7.3%. In addition to the impact from the weak sales growth and currency headwinds, margins were affected by higher growth and Accelerate! investments at IG&S. Incremental cost savings in Q1 amounted to only EUR22m, but are likely to accelerate later this year given the year-end target of EUR1.25bn.

**More cautious outlook for 2014**
While management remains committed to its 2016 financial targets, 2014 will be a challenging year. Management had previously stated that 2014 would see a modest step towards the 2016 targets, but this statement was not repeated. As for healthcare, the EUR60-70m impact from the production suspension in Cleveland, Ohio, was previously expected to be largely recovered in H2, but is no longer the case due to currency and market headwinds. Consensus for 2014 to come down While management remains committed to the 11-12% margin target for 2016, forecasts for 2014 are to come down. Following 0.2% comparable sales growth and 70bps margin erosion in Q1, consensus for 2014 (4.4% growth, 50bps margin expansion) now looks far too optimistic. Taking into account that forecasts will come down, we don’t think valuation is particularly attractive and we fail to see a catalyst for the shares.
[+] source: Kepler Cheuvreux

About the author

John Adam
John Adam was one of the Invezz Founding Partners & Lead Editor's up until 2017. John has an unmatched breadth and depth of experience in all things investing, and we wish him the best in his pastures new.

Leave a Reply

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.